CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors. - Zouggari N; Trugenberger C; Du Bois V; Wang W; Rossetti GG; Halazonetis TD; Labidi-Galy I (Frontiers in oncology, 2025)